InMed Pharmaceuticals (FRA:MWG) Research & Development: €2.45 Mil (TTM As of Mar. 2026)


FRA:MWG InMed Pharmaceuticals Inc FRA:MWG
29 GF Score
Price €1.40
GF Value €0.78
! 4 Warning Signs
View Full Analysis

What is InMed Pharmaceuticals Research & Development?

InMed Pharmaceuticals FRA:MWG +0.72% 29 Research & Development is €2.45 Mil as of Mar. 2026. GuruFocus rates FRA:MWG with a GF Score™ of 29/100 and a GF Value™ of €0.78. The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. InMed Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was €0.89 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €2.45 Mil.

InMed Pharmaceuticals  (FRA:MWG) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

InMed Pharmaceuticals Research & Development Related Terms

InMed Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for InMed Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InMed Pharmaceuticals Research & Development Chart

InMed Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.43 6.89 3.45 2.99 2.47

InMed Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.53 0.50 0.54 0.89
FRA:MWG
29GF Score
InMed Pharmaceuticals Inc FRA:MWG
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InMed Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2.45 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €2.45 Mil mean?
InMed Pharmaceuticals (FRA:MWG) has a Research & Development of €2.45 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on InMed Pharmaceuticals and its competitors.
Is InMed Pharmaceuticals' Research & Development too high?
InMed Pharmaceuticals' current Research & Development is €2.45 Mil. Overall, InMed Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does InMed Pharmaceuticals' Research & Development compare to SNOA and CVSI?
InMed Pharmaceuticals' Research & Development of €2.45 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on InMed Pharmaceuticals and its competitors. InMed Pharmaceuticals's current Research & Development is €2.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InMed Pharmaceuticals stock overvalued right now?
InMed Pharmaceuticals (FRA:MWG) has a current Research & Development of €2.45 Mil. The stock's GF Value™ is €0.78, compared to a current price of €1.40 — trading 79.5% above its estimated fair value. The current Research & Development is €2.45 Mil. InMed Pharmaceuticals' overall GF Score™ is 29/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For InMed Pharmaceuticals (FRA:MWG), the current Research & Development is €2.45 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InMed Pharmaceuticals (FRA:MWG) Overvalued in 2026?

Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued. The current stock price of €1.40 is trading 79.5% above its estimated GF Value™ of €0.78.

Key valuation signals for FRA:MWG:

  • Research & Development: €2.45 Mil
  • GF Value™: €0.78 vs. price of €1.40 (79.5% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the FRA:MWG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InMed Pharmaceuticals Business Description

Other Exchanges INM:USA
Address 885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
29GF Score

Get the complete analysis for FRA:MWG

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.40
Price
€0.78
GF Value